Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP [...]

Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C financing. Participants include Delphi Ventures, Versant Ventures, US Venture Partners and Domain Associates. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Sage Therapeutics (Watertown, MA) a development-stage pharmaceutical company focused on modulators of neuronal activity for schizophrenia, depression, pain and traumatic brain injury, closed a $35M Series A financing. Participants include Third Rock Ventures.

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

PharmacoFore (San Carlos, CA) a clinical-stage biopharmaceutical company focused on improvement of existing drugs preventing misuse, abuse, and overdose of prescription medications for pain, closed a $10M Series A financing. Participants include Founders Fund.

MSI Methylation Sciences (Canada) a preclinical-stage pharmaceutical company focused on depression, closed a $18.2M Series A financing. Participants include Inventages, GrowthWorks and BC Advantage Funds.

Prexa Pharmaceuticals (Boston, MA) a preclinical-stage biotechnology company focused on ADHD, depression, Parkinson’s and other CNS related diseases, closed a $7.0M Series B financing. Participants include Advent Healthcare Ventures and Shire.

Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

« Previous Entries  Next Page »

to top of page...